Arcturus Therapeutics Holdings 주식 주식분석 | 주식가격 | 뉴스 | ARCT | US03969T1097 | A2PMAS

날짜	Arcturus Therapeutics Holdings 주식 가격
	25.48 undefined
	25.25 undefined
	23.21 undefined
	22.03 undefined
	21.77 undefined
	21.31 undefined
	21.74 undefined
	21.15 undefined
	20.61 undefined
	21.02 undefined
	20.55 undefined
	21.01 undefined
	20.61 undefined
	20.75 undefined
	19.91 undefined
	20.98 undefined
	19.76 undefined
	19.00 undefined
	18.69 undefined
	18.82 undefined
	19.06 undefined

날짜	Arcturus Therapeutics Holdings 매출	Arcturus Therapeutics Holdings EBIT	Arcturus Therapeutics Holdings 이익
2029e	1.36 조. undefined	0 undefined	506.75 백만 undefined
2028e	1.04 조. undefined	591.63 백만 undefined	392.66 백만 undefined
2027e	567.75 백만 undefined	194.23 백만 undefined	135.42 백만 undefined
2026e	361.73 백만 undefined	90.42 백만 undefined	19.75 백만 undefined
2025e	199.03 백만 undefined	-45.85 백만 undefined	-59.72 백만 undefined
2024e	189.25 백만 undefined	-95.36 백만 undefined	-83.51 백만 undefined
2023	166.8 백만 undefined	-78.21 백만 undefined	-29.73 백만 undefined
2022	206 백만 undefined	12.2 백만 undefined	9.3 백만 undefined
2021	12.4 백만 undefined	-202.9 백만 undefined	-203.7 백만 undefined
2020	9.5 백만 undefined	-71.5 백만 undefined	-72.1 백만 undefined
2019	20.8 백만 undefined	-25.5 백만 undefined	-26 백만 undefined
2018	15.8 백만 undefined	-21.8 백만 undefined	-21.8 백만 undefined
2017	13 백만 undefined	-10.5 백만 undefined	-10.9 백만 undefined
2016	20.4 백만 undefined	-1 백만 undefined	-1.6 백만 undefined
2015	0 undefined	-19.7 백만 undefined	-19.4 백만 undefined
2014	0 undefined	-33.1 백만 undefined	-32.8 백만 undefined
2013	0 undefined	-10.3 백만 undefined	-10.5 백만 undefined
2012	0 undefined	-1.5 백만 undefined	-1.6 백만 undefined
2011	0 undefined	-3.9 백만 undefined	-3.9 백만 undefined

	매출	EBIT	이익
2011	0 USD	-3.9 백만 USD	-3.9 백만 USD
2012	0 USD	-1.5 백만 USD	-1.6 백만 USD
2013	0 USD	-10.3 백만 USD	-10.5 백만 USD
2014	0 USD	-33.1 백만 USD	-32.8 백만 USD
2015	0 USD	-19.7 백만 USD	-19.4 백만 USD
2016	20.4 백만 USD	-1 백만 USD	-1.6 백만 USD
2017	13 백만 USD	-10.5 백만 USD	-10.9 백만 USD
2018	15.8 백만 USD	-21.8 백만 USD	-21.8 백만 USD
2019	20.8 백만 USD	-25.5 백만 USD	-26 백만 USD
2020	9.5 백만 USD	-71.5 백만 USD	-72.1 백만 USD
2021	12.4 백만 USD	-202.9 백만 USD	-203.7 백만 USD
2022	206 백만 USD	12.2 백만 USD	9.3 백만 USD
2023	166.8 백만 USD	-78.21 백만 USD	-29.73 백만 USD
2024e	189.25 백만 USD	-95.36 백만 USD	-83.51 백만 USD
2025e	199.03 백만 USD	-45.85 백만 USD	-59.72 백만 USD
2026e	361.73 백만 USD	90.42 백만 USD	19.75 백만 USD
2027e	567.75 백만 USD	194.23 백만 USD	135.42 백만 USD
2028e	1.04 조. USD	591.63 백만 USD	392.66 백만 USD
2029e	1.36 조. USD	0 USD	506.75 백만 USD

2011	2012	2013	2014	2015	2016	2017	2018	2019	2020	2021	2022	2023	2024e	2025e	2026e	2027e	2028e	2029e
0	0	0	0	0	0.02	0.01	0.02	0.02	0.01	0.01	0.21	0.17	0.19	0.2	0.36	0.57	1.04	1.36
-	-	-	-	-	-	-35.00	15.38	33.33	-55.00	33.33	1,616.67	-19.42	13.86	5.29	81.41	57.06	83.25	30.80
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
-3	-1	-10	-33	-19	-1	-10	-21	-25	-71	-202	12	-78	-95	-45	90	194	591	0
-	-	-	-	-	-5.00	-76.92	-140.00	-125.00	-788.89	-1,683.33	5.83	-46.99	-50.26	-22.61	24.93	34.22	56.88	-
-3	-1	-10	-32	-19	-1	-10	-21	-26	-72	-203	9	-29	-83	-59	19	135	392	506
-	-66.67	900.00	220.00	-40.63	-94.74	900.00	110.00	23.81	176.92	181.94	-104.43	-422.22	186.21	-28.92	-132.20	610.53	190.37	29.08
1.1	1.1	1.5	2	3.1	2	3.1	10.1	12.1	20.3	26.3	27.1	26.63	0	0	0	0	0	0
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-

2011	2012	2013	2014	2015	2016	2017	2018	2019	2020	2021	2022	2023

0.6	0.1	50.1	21.7	50.7	8.3	48.6	36.7	71.4	462.9	370.5	391.9	292.01
0	0	0	0	0	3.6	0.5	4.5	2.2	2.1	3.4	2.8	32.06
0	0	0	0	0	0	0	0	0	0	0	0	0
0	0	0	0	0	0	0	0	0	0	0	0	0
0	0.1	0.1	0.3	1.6	0.3	1.8	0.6	0.8	2.8	5.1	8.7	62.52
0.6	0.2	50.2	22	52.3	12.2	50.9	41.8	74.4	467.8	379	403.4	386.59
0	0	0	0.1	0.2	1.3	1	2	7.5	8.6	11.3	45	40.93
0.5	0	0	0	19	0	0	0.3	0.3	0	0.5	0	0
0	0	0	0	0	0	0	0	0	0	0	0	0
0	0	0	0	0	0	0	0	0	0	0	0	0
0	0	0	0	0	0	0	0	0	0	0	0	0
0	0	0.1	0.1	0.1	0.1	0.1	0.1	0.1	0.1	2.1	2.1	1.89
0.5	0	0.1	0.2	19.3	1.4	1.1	2.4	7.9	8.7	13.9	47.1	42.81
1.1	0.2	50.3	22.2	71.6	13.6	52	44.2	82.3	476.5	392.9	450.5	429.4

0	0	0	0	100	0	200	200	0	0	0	0	27
7.6	7.6	67.4	71.5	140.3	13.8	56.7	58.3	97.4	540.3	575.7	608.4	646.35
-6.6	-8.2	-18.7	-51.6	-71	-12.2	-23.1	-44.9	-71.7	-143.8	-347.5	-338.1	-367.87
0	0	0	0	0	0	0	0	0	0	0	0	0
0	0	0	0	0	0	0	0	0	0	0	0	0
1	-0.6	48.7	19.9	69.4	1.6	33.8	13.6	25.7	396.5	228.2	270.3	278.51
0.1	0	0	0.3	0.1	3.4	1.8	2.4	5.8	10.8	10.1	7.4	5.28
0.1	0.1	1.5	2	2.2	0.4	1.8	3.9	4.4	19.4	23.5	30.2	31.88
0	0	0.1	0.1	0.1	4.9	7.4	6.3	11.1	18.1	43.5	28.6	44.83
0	700	0	0	0	100	0	0	0	0	0	0	0
0	0	0	0	0	0	0	0	0	1.3	22.5	60.7	0
0.2	0.8	1.6	2.4	2.4	8.8	11	12.6	21.3	49.6	99.6	126.9	81.99
0	0	0	0	0	0	0	9.9	15	13.8	40.6	0	0
0	0	0	0	0	0	0	0	0	0	0	0	0
0	0	0	0	0	3.4	7.2	8.1	20	16.5	24.4	53.1	68.9
0	0	0	0	0	3.4	7.2	18	35	30.3	65	53.1	68.9
0.2	0.8	1.6	2.4	2.4	12.2	18.2	30.6	56.3	79.9	164.6	180	150.89
1.2	0.2	50.3	22.3	71.8	13.8	52	44.2	82	476.4	392.8	450.3	429.4

2011	2012	2013	2014	2015	2016	2017	2018	2019	2020	2021	2022	2023
-3	-1	-10	-32	-19	-1	-10	-21	-25	-72	-203	9	-29
0	0	0	0	0	0	0	0	0	0	1	1	2
0	0	0	0	0	0	0	0	0	0	0	0	0
0	0	1	0	-1	-2	7	-1	15	21	31	-12	7
3	0	3	8	2	1	4	2	4	13	65	64	35
0	0	0	0	0	0	0	0	0	0	0	0	2
0	0	0	0	0	0	0	0	0	0	0	0	0
-2	-1	-7	-28	-18	-2	0	-20	-6	-42	-135	31	-18
0	0	0	0	0	0	0	-1	0	-1	-3	-7	-2
-1	1	-28	8	-33	0	10	22	0	-1	-3	-7	-2
-1	1	-28	8	-33	0	10	23	0	0	0	0	0
0	0	0	0	0	0	0	0	0	0	0	0	0
0	0	0	0	0	0	5	9	4	0	46	-5	-27
2	0	57	0	66	0	1	0	36	436	1	2	3
2	0	57	0	66	0	7	10	41	436	48	-2	-24
-	-	-	-	-	-	-	-	-	-	-	-	-
0	0	0	0	0	0	0	0	0	0	0	0	0
0	0	22	-19	14	-3	16	11	34	391	-90	21	-45
-2.38	-1.58	-7.39	-28.41	-18.33	-3.55	-0.71	-22.24	-7.27	-44.6	-138.45	24.26	-21
0	0	0	0	0	0	0	0	0	0	0	0	0

Arcturus Therapeutics Holdings 브루토마진	Arcturus Therapeutics Holdings EBIT-마진	Arcturus Therapeutics Holdings 이익 마진
2029e	0 %	37.29 %
2028e	56.94 %	37.79 %
2027e	34.21 %	23.85 %
2026e	25 %	5.46 %
2025e	-23.04 %	-30.01 %
2024e	-50.39 %	-44.13 %
2023	-46.89 %	-17.82 %
2022	5.92 %	4.51 %
2021	-1,636.29 %	-1,642.74 %
2020	-752.63 %	-758.95 %
2019	-122.6 %	-125 %
2018	-137.97 %	-137.97 %
2017	-80.77 %	-83.85 %
2016	-4.9 %	-7.84 %
2015	0 %	0 %
2014	0 %	0 %
2013	0 %	0 %
2012	0 %	0 %
2011	0 %	0 %

	EBIT-마진	이익 마진
2011	0 %	0 %
2012	0 %	0 %
2013	0 %	0 %
2014	0 %	0 %
2015	0 %	0 %
2016	-4.9 %	-7.84 %
2017	-80.77 %	-83.85 %
2018	-137.97 %	-137.97 %
2019	-122.6 %	-125 %
2020	-752.63 %	-758.95 %
2021	-1,636.29 %	-1,642.74 %
2022	5.92 %	4.51 %
2023	-46.89 %	-17.82 %
2024e	-50.39 %	-44.13 %
2025e	-23.04 %	-30.01 %
2026e	25 %	5.46 %
2027e	34.21 %	23.85 %
2028e	56.94 %	37.79 %
2029e	0 %	37.29 %

날짜	Arcturus Therapeutics Holdings 주당 매출	Arcturus Therapeutics Holdings EBIT 당 주식	Arcturus Therapeutics Holdings 주당 이익
2029e	50.26 undefined	0 undefined	18.74 undefined
2028e	38.42 undefined	0 undefined	14.52 undefined
2027e	21 undefined	0 undefined	5.01 undefined
2026e	13.38 undefined	0 undefined	0.73 undefined
2025e	7.36 undefined	0 undefined	-2.21 undefined
2024e	7 undefined	0 undefined	-3.09 undefined
2023	6.26 undefined	-2.94 undefined	-1.12 undefined
2022	7.6 undefined	0.45 undefined	0.34 undefined
2021	0.47 undefined	-7.71 undefined	-7.75 undefined
2020	0.47 undefined	-3.52 undefined	-3.55 undefined
2019	1.72 undefined	-2.11 undefined	-2.15 undefined
2018	1.56 undefined	-2.16 undefined	-2.16 undefined
2017	4.19 undefined	-3.39 undefined	-3.52 undefined
2016	10.2 undefined	-0.5 undefined	-0.8 undefined
2015	0 undefined	-6.35 undefined	-6.26 undefined
2014	0 undefined	-16.55 undefined	-16.4 undefined
2013	0 undefined	-6.87 undefined	-7 undefined
2012	0 undefined	-1.36 undefined	-1.45 undefined
2011	0 undefined	-3.55 undefined	-3.55 undefined

	주당 매출	EBIT 당 주식	주당 이익
2011	0 USD	-3.55 USD	-3.55 USD
2012	0 USD	-1.36 USD	-1.45 USD
2013	0 USD	-6.87 USD	-7 USD
2014	0 USD	-16.55 USD	-16.4 USD
2015	0 USD	-6.35 USD	-6.26 USD
2016	10.2 USD	-0.5 USD	-0.8 USD
2017	4.19 USD	-3.39 USD	-3.52 USD
2018	1.56 USD	-2.16 USD	-2.16 USD
2019	1.72 USD	-2.11 USD	-2.15 USD
2020	0.47 USD	-3.52 USD	-3.55 USD
2021	0.47 USD	-7.71 USD	-7.75 USD
2022	7.6 USD	0.45 USD	0.34 USD
2023	6.26 USD	-2.94 USD	-1.12 USD
2024e	7 USD	0 USD	-3.09 USD
2025e	7.36 USD	0 USD	-2.21 USD
2026e	13.38 USD	0 USD	0.73 USD
2027e	21 USD	0 USD	5.01 USD
2028e	38.42 USD	0 USD	14.52 USD
2029e	50.26 USD	0 USD	18.74 USD

Segmente	2022
Collaboration Revenue	205.76 백만 USD
Grant Revenue	244,000 USD

	Collaboration Revenue	Grant Revenue
2022	205.76 백만 USD	244,000 USD

날짜	Foreign countries
2022	192.7 백만 USD
2021	5 백만 USD
2020	1 백만 USD
2019	7 백만 USD

	Foreign countries
2019	7 백만 USD
2020	1 백만 USD
2021	5 백만 USD
2022	192.7 백만 USD

	주식 수량
2011	1.1 백만 Aktien
2012	1.1 백만 Aktien
2013	1.5 백만 Aktien
2014	2 백만 Aktien
2015	3.1 백만 Aktien
2016	2 백만 Aktien
2017	3.1 백만 Aktien
2018	10.1 백만 Aktien
2019	12.1 백만 Aktien
2020	20.3 백만 Aktien
2021	26.3 백만 Aktien
2022	27.1 백만 Aktien
2023	26.63 백만 Aktien
2024e	26.63 백만 Aktien
2025e	26.63 백만 Aktien
2026e	26.63 백만 Aktien
2027e	26.63 백만 Aktien
2028e	26.63 백만 Aktien
2029e	26.63 백만 Aktien

EPS-예상치	EPS-실제	보고 분기
-1.63	-0.64 (60.74 %)	2024 Q2
-1.21	-1 (17.53 %)	2024 Q1
-1.01	-0.32 (68.38 %)	2023 Q4
-1.73	-0.61 (64.65 %)	2023 Q3
-0.22	-1.98 (-820.93 %)	2023 Q2
0.06	1.87 (2,970.61 %)	2023 Q1
1	4.43 (343.8 %)	2022 Q4
-1.85	-1.33 (28.13 %)	2022 Q3
-1.94	-0.82 (57.69 %)	2022 Q2
-1.47	-1.94 (-32.29 %)	2022 Q1
-1.76	-1.47 (16.39 %)	2021 Q4
-1.62	-2.05 (-26.2 %)	2021 Q3
-2.19	-2.07 (5.51 %)	2021 Q2
-1.28	-2.15 (-68.19 %)	2021 Q1
-0.9	-1.25 (-39.24 %)	2020 Q4
-0.5	-0.92 (-85.11 %)	2020 Q3
-0.56	-0.55 (2.36 %)	2020 Q2
-0.62	-0.67 (-8.19 %)	2020 Q1
-0.54	-0.76 (-39.83 %)	2019 Q4
-0.37	-0.56 (-51.68 %)	2019 Q3
-0.65	-0.07 (89.19 %)	2019 Q2
-0.59	-0.65 (-10.34 %)	2019 Q1
-0.49	-0.08 (83.83 %)	2018 Q4
-0.57	-0.42 (26.47 %)	2018 Q3
-0.71	-0.99 (-38.66 %)	2018 Q2
-0.67	-0.66 (1.96 %)	2018 Q1
-0.47	-1.08 (-130.18 %)	2017 Q4
-2.71	-0.7 (74.2 %)	2017 Q3
-0.96	-0.91 (5.59 %)	2017 Q2
-1.29	-0.91 (29.19 %)	2017 Q1
-1.94	-1.54 (20.61 %)	2016 Q4
-1.84	-1.96 (-6.6 %)	2016 Q3
-1.56	-1.47 (5.81 %)	2016 Q2
-1.54	-1.26 (18.3 %)	2016 Q1
-1.71	-1.4 (18.3 %)	2015 Q4
-2.21	-1.4 (36.75 %)	2015 Q3
-2.05	-1.68 (17.92 %)	2015 Q2
-2.05	-1.82 (11.08 %)	2015 Q1
-4.28	-3.5 (18.3 %)	2014 Q4
-3.97	-5.39 (-35.84 %)	2014 Q3
-3.78	-3.99 (-5.44 %)	2014 Q2
-2.91	-3.71 (-27.51 %)	2014 Q1
-2.25	-3.15 (-40.06 %)	2013 Q4
-0.64	-1.96 (-205.01 %)	2013 Q3
-0.43	-0.42 (1.96 %)	2013 Q2

%-지분	이름	주식	변경
7.13800 %	BlackRock Institutional Trust Company, N.A.	1,930,116	192,218
6.24870 %	ARK Investment Management LLC	1,689,649	-358,038
6.02687 %	State Street Global Advisors (US)	1,629,666	-38,259
5.47373 %	Payne (Joseph E)	1,480,097	0
5.37392 %	The Vanguard Group, Inc.	1,453,107	51,537
4.72085 %	Nikko Asset Management Co., Ltd.	1,276,519	-44,133
4.02711 %	Dimensional Fund Advisors, L.P.	1,088,930	115,087
3.95641 %	Woodline Partners LP	1,069,814	0
3.19659 %	Fidelity Management & Research Company LLC	864,358	-75,923
2.04954 %	Morgan Stanley & Co. LLC	554,196	1,647
17.42423 %	Federated Hermes Global Investment Management Corp.	4,711,512	0
1.99063 %	Geode Capital Management, L.L.C.	538,265	26,097
1.75092 %	Chivukula (Padmanabh)	473,448	-26,000
1.66555 %	Granahan Investment Management, LLC	450,366	51,504
1.48477 %	Schonfeld Strategic Advisors LLC	401,481	294,325
1.34003 %	Jupiter Asset Management Ltd.	362,344	167,563
1.06708 %	Goldman Sachs & Company, Inc.	288,538	32,185
1.06367 %	JPMorgan Asset Management U.K. Limited	287,616	-5,074
1.00047 %	Sassine (Andy H)	270,526	1,223
0.92235 %	BlackRock Financial Management, Inc.	249,404	55,542
0.76600 %	Great Lakes Advisors, LLC	207,127	207,127
0.75662 %	Northern Trust Investments, Inc.	204,589	19,515
0.71579 %	Nuveen LLC	193,549	-797
0.68902 %	Charles Schwab Investment Management, Inc.	186,310	2,369
0.59996 %	Nikko Asset Management Americas, Inc.	162,229	-34,469
0.59125 %	AQR Capital Management, LLC	159,873	-12,329
0.53940 %	Portolan Capital Management, L.L.C.	145,854	-130,651
0.49430 %	Millennium Management LLC	133,660	56,297
0.48016 %	Royce Investment Partners	129,836	0
0.46636 %	Goldman Sachs Asset Management, L.P.	126,103	36,971
0.44527 %	ACT Capital Management, L.L.C.	120,400	-106,200
0.41854 %	Rafferty Asset Management LLC	113,172	-19,609
0.40854 %	Tri Locum Partners LP	110,470	-98,416
0.38493 %	BlackRock Advisors (UK) Limited	104,085	1,005
0.36887 %	Connor, Clark & Lunn Investment Management Ltd.	99,742	64,520
0.35342 %	Farrell (Peter Craig)	95,565	0
0.34452 %	BlackRock Asset Management Ireland Limited	93,159	-2,346
0.32614 %	Susquehanna International Group, LLP	88,189	31,876
0.31991 %	Numeric Investors LLC	86,503	31,875
0.31242 %	Barclays Bank PLC	84,478	12,175
0.27291 %	D. E. Shaw & Co., L.P.	73,795	29,166
0.27213 %	Assenagon Asset Management S.A.	73,585	55,237
0.26889 %	UBS Financial Services, Inc.	72,708	44,522
0.26670 %	BNY Mellon Asset Management	72,115	1,788
0.26389 %	Jane Street Capital, L.L.C.	71,356	-7,608
0.25542 %	BlackRock Investment Management, LLC	69,065	2,713
0.24364 %	Wells Fargo Advisors	65,880	-15,014
0.24024 %	Qube Research & Technologies Ltd	64,960	-90,496
0.23299 %	OMERS Administration Corporation	63,000	63,000
0.22500 %	Wellington Management Company, LLP	60,841	17,491
0.22064 %	Mellon Investments Corporation	59,662	36,642
0.21452 %	Putnam Investment Management, L.L.C.	58,006	-1,839
0.18685 %	Advantage Alpha Capital Partners LP	50,524	50,524
0.18074 %	Citi Investment Research (US)	48,872	-8,453
0.17467 %	Bank Julius Bär & Co. AG	47,232	-11,028
0.17456 %	Schweizerische Nationalbank	47,200	-5,400
0.16810 %	Jacobs Levy Equity Management, Inc.	45,454	36,128
0.15987 %	Dimensional Fund Advisors, Ltd.	43,230	419
0.15291 %	Neuberger Berman, LLC	41,348	41,348
0.15243 %	MFS Investment Management	41,217	3,457
0.14793 %	Deka Vermögensmanagement GmbH	40,000	0
0.14361 %	Northern Trust Global Investments	38,833	3,656
0.13774 %	Credit Suisse Funds AG	37,246	-6,686
0.13372 %	Rhumbline Advisers Ltd. Partnership	36,159	-278
0.12683 %	State of Wisconsin Investment Board	34,295	15,277
0.12307 %	SG Americas Securities, L.L.C.	33,278	-42,567
0.11808 %	Hennion & Walsh Asset Management, Inc.	31,930	778
0.10931 %	Allspring Global Investments, LLC	29,557	-85,253
0.10868 %	Campbell & Company, Inc.	29,386	29,386
0.10436 %	Alps Advisors, Inc.	28,220	-2,103
0.10382 %	TritonPoint Wealth, LLC	28,072	28,072
0.10310 %	Lazard Asset Management, L.L.C.	27,878	18,161
0.09955 %	Diametric Capital	26,918	788
0.09944 %	BofA Global Research (US)	26,889	-66,822
0.09490 %	Two Sigma Investments, LP	25,660	5,100
0.09470 %	Avantis Investors	25,607	12,305
0.09397 %	AllianceBernstein L.P.	25,410	0
0.09330 %	Columbia Threadneedle Investments (US)	25,228	16,443
0.09320 %	State Teachers Retirement System of Ohio	25,200	4,000
0.09310 %	California State Teachers Retirement System	25,174	-1,095
0.09224 %	Marquet (Magda)	24,942	2,222
0.09157 %	Jefferies LLC	24,760	24,760
0.09056 %	MGO One Seven LLC	24,488	800
0.08910 %	Aviva Investors Global Services Limited	24,093	-4,431
0.08602 %	BNP Paribas Securities Corp. North America	23,259	682
0.08541 %	Aperio Group, LLC	23,096	3,667
0.08503 %	SummerHaven Investment Management, LLC	22,991	287
0.07979 %	Arrowstreet Capital, Limited Partnership	21,576	21,576
0.07771 %	Legal & General Investment Management Ltd.	21,013	681
0.07597 %	KEPLER-FONDS Kapitalanlagegesellschaft m.b.H.	20,542	20,542
0.07474 %	PGIM Quantitative Solutions LLC	20,210	13,710
0.07408 %	Fubon Asset Management Company Ltd.	20,030	-628
0.07396 %	Banque Pictet & Cie S.A.	20,000	0
0.07032 %	DWS Investment Management Americas, Inc.	19,015	0
0.07014 %	HRT Financial LP	18,966	18,966
0.06918 %	William Blair & Company, L.L.C. (Research)	18,705	0
0.06814 %	ProFund Advisors LLC	18,424	-3,874
0.06501 %	Point72 Asset Management, L.P.	17,578	-317,700
0.06497 %	Mirae Asset Global Investments (USA) LLC	17,569	-376
0.06399 %	BlackRock Investment Management (UK) Ltd.	17,303	4,251

이름	관계	이주간 상관관계	원월 상관관계	삼개월 상관계수	여섯달 상관관계	일년간 상관관계	이년 상관관계
Arbutus Biopharma	공급업체고객	0,94	0,79	0,69	0,89	0,70	0,56
Catalent	공급업체고객	0,93	0,25	0,71	0,90	0,90	0,02
Danaher	공급업체고객	0,80	0,77	0,89	0,92	0,83	-0,32
CureVac	공급업체고객	0,62	0,39	0,68	0,89	0,78	-
Takeda Pharmaceutical	공급업체고객	0,47	0,17	-0,19	-0,77	-0,02	0,18
Ultragenyx Pharmaceutical	공급업체고객	0,02	0,80	0,80	0,81	0,79	0,75
Johnson & Johnson	공급업체고객	-0,53	-0,45	-0,20	-0,60	-0,25	-0,55

What values and corporate philosophy does Arcturus Therapeutics Holdings represent?

Arcturus Therapeutics Holdings Inc represents a commitment to revolutionizing the field of RNA medicines. The company focuses on developing breakthrough therapies to address unmet medical needs. Arcturus Therapeutics places a strong emphasis on creating value for patients, healthcare providers, and shareholders. With a patient-centric approach, the company aims to drive innovative advancements in the RNA therapeutic space. Arcturus Therapeutics also upholds a philosophy of collaboration and partnerships to accelerate the development and commercialization of transformative medicines. By combining scientific expertise and a forward-thinking mindset, the company strives to improve the lives of individuals worldwide through cutting-edge RNA-based therapies.

In which countries and regions is Arcturus Therapeutics Holdings primarily present?

Arcturus Therapeutics Holdings Inc primarily operates in the United States, focusing on the development and commercialization of RNA therapeutics.

What significant milestones has the company Arcturus Therapeutics Holdings achieved?

Arcturus Therapeutics Holdings Inc has achieved several significant milestones. Firstly, the company successfully developed and gained approval for its COVID-19 vaccine candidate, ARCT-021. Additionally, Arcturus Therapeutics entered into partnerships with global pharmaceutical companies to facilitate the production and distribution of their vaccine technology. The company also received funding from various organizations, including the Singapore Economic Development Board. Moreover, Arcturus Therapeutics expanded its pipeline by initiating clinical trials for therapies targeting various diseases, including rare liver diseases and viral hepatitis. These achievements demonstrate the company's dedication to advancing innovative therapeutics and its commitment to addressing unmet medical needs.

What is the history and background of the company Arcturus Therapeutics Holdings?

Arcturus Therapeutics Holdings Inc. is a renowned biotechnology company specializing in the development of RNA medicines. Founded in 2013, the company is headquartered in San Diego, California. Arcturus Therapeutics focuses on leveraging its proprietary technologies, including LUNAR® and STARR™, to develop innovative therapeutics for various diseases. With a strong emphasis on messenger RNA (mRNA) medicines, Arcturus aims to revolutionize the treatment landscape by providing safe and efficient therapies. Additionally, the company has strategic collaborations and partnerships with leading organizations to accelerate therapeutic advancements. Arcturus Therapeutics Holdings Inc. continues to strive towards advancing RNA medicines to address unmet medical needs globally.

Who are the main competitors of Arcturus Therapeutics Holdings in the market?

The main competitors of Arcturus Therapeutics Holdings Inc in the market are Moderna Inc, BioNTech SE, and Translate Bio Inc.

In which industries is Arcturus Therapeutics Holdings primarily active?

Arcturus Therapeutics Holdings Inc is primarily active in the biotechnology and pharmaceutical industries.

What is the business model of Arcturus Therapeutics Holdings?

The business model of Arcturus Therapeutics Holdings Inc is focused on developing and commercializing RNA-based therapeutics. The company utilizes its proprietary LUNAR® lipid-mediated delivery system to enable efficient and targeted delivery of RNA medicines. Arcturus Therapeutics aims to address unmet medical needs through the development of novel RNA therapies for various diseases. The company leverages its expertise in RNA science and drug delivery technology to advance a robust pipeline of potential treatments. Arcturus Therapeutics partners with pharmaceutical companies and research organizations to accelerate the development and commercialization of its innovative therapies.

Arcturus Therapeutics Holdings 2024의 P/E 비율은 얼마입니까?

Arcturus Therapeutics Holdings의 P/E 비율은 -8.12입니다.

Arcturus Therapeutics Holdings 2024의 KUV는 얼마입니까?

Arcturus Therapeutics Holdings의 P/S 비율은 3.59입니다.

Arcturus Therapeutics Holdings의 AlleAktien 품질 점수는 얼마인가요?

Arcturus Therapeutics Holdings에 대한 AlleAktien 품질 점수는 4/10입니다.

Arcturus Therapeutics Holdings 2024의 매출은 얼마인가요?

예상되는 Arcturus Therapeutics Holdings 매출은 189.25 백만 USD입니다.

Arcturus Therapeutics Holdings 2024의 이익은 얼마인가요?

예상되는 Arcturus Therapeutics Holdings 이익은 -83.51 백만 USD입니다.

Arcturus Therapeutics Holdings은 무엇을 하나요?

Arcturus Therapeutics is a biopharmaceutical company that focuses on RNA-based therapies and vaccines. The company's business model is centered around the development and commercialization of therapy products based on their proprietary technology platform. They offer a wide range of RNA-based therapies for severe and rare diseases that currently do not have satisfactory treatments. They also provide services to support the development of mRNA-based therapy products for biotechnology and pharmaceutical companies. Arcturus Therapeutics has developed a technology platform for the rapid and effective development of vaccines against infectious diseases using RNA technology. They collaborate with strategic partners such as Ultragenyx Pharmaceutical and Janssen Pharmaceuticals to optimize RNA technologies for therapy and vaccine production. Arcturus Therapeutics utilizes proprietary technology platforms including the STARR platform for gene silencing and the LUNAR platform for therapeutic use of mRNA. The company has gained significant attention and success in the field of RNA technology and has established a strong position in the market. With a strong pipeline of RNA-based therapies and vaccines, Arcturus will continue to play an important role in the biopharmaceutical industry.

Arcturus Therapeutics Holdings 배당금은 얼마입니까?

Arcturus Therapeutics Holdings은(는) 연간 번의 배당을 통해 0 USD의 배당금을 지급합니다.

Arcturus Therapeutics Holdings이 얼마나 자주 배당을 지급하나요?

Arcturus Therapeutics Holdings의 현재 배당금은 계산할 수 없거나, 회사가 배당금을 지급하지 않습니다.

Arcturus Therapeutics Holdings ISIN이 무엇입니까?

Arcturus Therapeutics Holdings의 ISIN은 US03969T1097입니다.

Arcturus Therapeutics Holdings WKN은 무엇인가요?

Arcturus Therapeutics Holdings의 WKN은 A2PMAS입니다.

Arcturus Therapeutics Holdings 티커는 무엇인가요?

Arcturus Therapeutics Holdings의 티커는 ARCT입니다.

Arcturus Therapeutics Holdings이 얼마만큼의 배당금을 지급합니까?

지난 12개월 동안 Arcturus Therapeutics Holdings은(는) 의 배당금을 지급했습니다. 이는 약 의 배당 수익률에 해당합니다. 향후 12개월 동안 Arcturus Therapeutics Holdings은(는) 0 USD의 배당금을 지급할 것으로 예상됩니다.

Arcturus Therapeutics Holdings의 배당 수익률은 얼마입니까?

Arcturus Therapeutics Holdings의 현재 배당 수익률은 입니다.

Arcturus Therapeutics Holdings의 배당금은 언제 지급되나요?

Arcturus Therapeutics Holdings은 분기별로 배당금을 지급합니다. 이는 월에 배당됩니다.

Arcturus Therapeutics Holdings의 배당금은 얼마나 안전한가요?

Arcturus Therapeutics Holdings은(는) 지난 0년 동안 매년 배당금을 지급했습니다.

Arcturus Therapeutics Holdings의 배당금은 얼마입니까?

향후 12개월 동안 0 USD의 배당금이 예상됩니다. 이는 배당수익률 0 %에 해당합니다.

Arcturus Therapeutics Holdings이(가) 속해 있는 섹터는 어디인가요?

Arcturus Therapeutics Holdings은 '건강' 섹터에 속합니다.

Wann musste ich die Aktien von Arcturus Therapeutics Holdings kaufen, um die vorherige Dividende zu erhalten?

Arcturus Therapeutics Holdings의 마지막 배당금을 0 USD만큼 받기 위해선 의 Ex-Tag 전에 주식을 보유하고 있어야 했습니다.

Arcturus Therapeutics Holdings의 마지막 배당금 지급일은 언제였습니까?

마지막 배당금 지급일은 입니다.

Arcturus Therapeutics Holdings의 2023년도 배당금은 얼마였습니까?

2023년에 Arcturus Therapeutics Holdings는 0 USD를 배당금으로 지급했습니다.

Arcturus Therapeutics Holdings는 어떤 화폐로 배당금을 지급하나요?

Arcturus Therapeutics Holdings의 배당금은 USD에 지급됩니다.

Scope 1 - 직접 방출	—
스코프 2 - 구매한 에너지로부터의 간접적인 배출	—
Scope 3 - 가치 창출 체인 내의 간접 배출	—
총 CO₂ 배출량	—
CO₂ 감소 전략	✅
석탄 에너지	❌
원자력	❌
동물 실험	✅
펠츠 & 레더	—
살충제	—
팜 오일	—
담배	❌
유전자 변형 생물체	❌
기후 개념	—
지속 가능한 임업	—
재활용 규정	❌
환경 친화적인 포장	❌
위험물질	❌
연료 소비량과 효율성	❌
물 사용량 및 효율성	❌

여성 직원 비율	—
관리 직위에서의 여성 비율	—
아시아 직원 비율	—
아시아 경영진 비율	—
히스패닉/라티노 직원 비율	—
히스패닉/라티노 관리 부문 지분	—
흑인 직원 비율	—
블랙 매니지먼트 지분	—
흰색 종업원의 비율	—
화이트 매니지먼트 지분	—
성인 콘텐츠	❌
알코올	❌
무기	—
총기	❌
도박	❌
군사 계약	❌
인권 개념	❌
개인정보 보호 정책	—
작업 및 건강 보호	❌
카톨릭	✅

환경 보고	❌
이해관계자 참여	❌
콜백 정책	❌
카르텔법	❌

Arcturus Therapeutics Holdings 티커	Arcturus Therapeutics Holdings FIGI
ARCT:US	BBG00NNW8JK1
ARCT:UA	BBG00NVC70T9
ARCT:UC	BBG00NVC70V6
ARCT:UN	BBG00NVC70X4
ARCT:UP	BBG00NVC70Y3
ARCT:UQ	BBG00NVC70Z2
ARCT:UB	BBG00NVC7108
ARCT:UM	BBG00NVC7126
ARCT:UX	BBG00NVC7135
ARCT:UD	BBG00NVC7180
ARCT:UF	BBG00NVC71C5
ARCT:VY	BBG00NVC71D4
ARCT:VJ	BBG00NVC71F2
ARCT:VK	BBG00NVC71G1
ARCT:VF	BBG00NVC71H0
ARCTGBP:XS	BBG00Q8HQ6R5
ARCTGBP:XH	BBG00Q8HQ6W9
ARCTGBP:XF	BBG00Q8HQ6Y7
ARCTGBP:XE	BBG00Q8HQ702
ARCTGBP:XJ	BBG00Q8HQ711
ARCTGBP:XL	BBG00Q8HQ720
ARCTGBP:XG	BBG00Q8HQ739
ARCTGBP:XO	BBG00Q8HQ748
ARCTGBP:XA	BBG00Q8HQ793
ARCTGBP:XT	BBG00Q8HQ7C9
ARCTGBP:XW	BBG00Q8HQ7D8
ARCTGBP:XU	BBG00Q8HQ7F6
ARCTGBP:XV	BBG00Q8HQ7H4
ARCTGBP:XM	BBG00Q8HQ7J2
ARCTGBP:EU	BBG00Q8HQ819
ARCTGUSD:EP	BBG00TZ0BF01
ARCTGUSD:EZ	BBG00TZ0BF29
ARCTGUSD:XS	BBG00TZ0BF38
ARCTGUSD:X2	BBG00TZ0BF47
ARCTGUSD:XH	BBG00TZ0BF65
ARCTGUSD:XF	BBG00TZ0BF83
ARCTGUSD:XE	BBG00TZ0BFB9
ARCTGUSD:XJ	BBG00TZ0BFC8
ARCTGUSD:XL	BBG00TZ0BFD7
ARCTGUSD:XG	BBG00TZ0BFF5
ARCTGUSD:XO	BBG00TZ0BFG4
ARCTGUSD:XA	BBG00TZ0BFL8
ARCTGUSD:E1	BBG00TZ0BFM7
ARCTGUSD:XT	BBG00TZ0BFN6
ARCTGUSD:XW	BBG00TZ0BFP4
ARCTGUSD:XU	BBG00TZ0BFQ3
ARCTGUSD:XV	BBG00TZ0BFS1
ARCTGUSD:XM	BBG00TZ0BFT0
ARCTGUSD:XQ	BBG00TZ0BFV7
ARCTGUSD:XX	BBG00TZ0BFW6
ARCTGUSD:XZ	BBG00TZ0BFX5
ARCTGUSD:X1	BBG00TZ0BFZ3
ARCTGUSD:EU	BBG00TZ0BG18
ARCT:VG	BBG00X1P4Q53
ARCT:VP	BBG00X1SL3H6

한 눈에 저평가된 주식을 인식하세요 fair value · 20 million securities worldwide · 50 year history · 10 year estimates · leading business news

가격

가격

티커ARCT

ISINUS03969T1097

WKNA2PMAS

Arcturus Therapeutics Holdings 주식 가격

가격

개요

인트라데이 기능

총 수익률 및 상대 가격 변동

해석 및 투자

Arcturus Therapeutics Holdings 주가 이력

Arcturus Therapeutics Holdings 주식 매출, EBIT, 이익 US03969T1097 · A2PMAS

매출, 이익 & EBIT

매출, EBIT, 소득 이해하기

연간 분석 및 비교

투자 기대치 활용

투자 통찰력

Arcturus Therapeutics Holdings 매출, 이익 및 EBIT 역사

Arcturus Therapeutics Holdings 주식 지표

손익계산서

매출 성장

총 이익률

EBIT와 EBIT 마진

수입과 성장

발행 주식

연간 비교의 해석

기대치와 예측

재무 상태표

재무 상태표 이해

자산

부채

자본

년대비 분석

데이터 해석

Arcturus Therapeutics Holdings 주식 마진 US03969T1097 · A2PMAS

마진

매출 총이익률 이해

EBIT 마진 분석

매출 마진에 대한 인사이트

기대치 해석

비교 분석

Arcturus Therapeutics Holdings 마진 역사

Arcturus Therapeutics Holdings 주식 매출, EBIT, 주당 순이익 US03969T1097 · A2PMAS

매출, EBIT 및 주당 이익

주당 매출

주당 EBIT

주당 수익

예상 값

Arcturus Therapeutics Holdings 매출, 이익 및 EBIT 주당 역사

Arcturus Therapeutics Holdings 주식 및 주식 분석

Arcturus Therapeutics Holdings 매출 세분화 US03969T1097 · A2PMAS

세그먼트별 매출

세그먼트별 매출 개요

해석 및 사용

투자 전략

Arcturus Therapeutics Holdings 매출 세분화

Arcturus Therapeutics Holdings 지역별 매출 US03969T1097 · A2PMAS

세그먼트별 매출

지역별 매출 개요

해석 및 사용법

투자 전략

Arcturus Therapeutics Holdings 매출 세분화

Arcturus Therapeutics Holdings Fair Value에 따른 평가

Fair Value

Fair Value 이해하기

수익 기반 Fair Value

매출 기반 Fair Value

배당 기반 Fair Value

기대치와 예측

비교 분석

Arcturus Therapeutics Holdings 역사적인 P/E, EBIT 및 P/S에 따른 평가

Arcturus Therapeutics Holdings 주식 수량 US03969T1097 · A2PMAS

매출, EBIT 및 주당 이익

주당 매출

주당 EBIT

주당 수익

예상 값

Arcturus Therapeutics Holdings 주식 분할

한 눈에 저평가된 주식을 인식하세요
fair value · 20 million securities worldwide · 50 year history · 10 year estimates · leading business news

티커
ARCT

ISIN
US03969T1097

WKN
A2PMAS